• Explore /
  • Poster
  • / Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized, phase II, multicenter, open-label study (DESTINY-Gastric01).

Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized, phase II, multicenter, open-label study (DESTINY-Gastric01).

Abstract Video & Slides Poster

Authors

Kohei Shitara

Kohei Shitara

National Cancer Center Hospital East, Chiba, Japan

Kohei Shitara , Yung-Jue Bang , Satoru Iwasa , Naotoshi Sugimoto , Min-hee Ryu , Daisuke Sakai , Hyun Cheol Chung , Hisato Kawakami , Hiroshi Yabusaki , Jeeyun Lee , Kaku Saito , Yoshinori Kawaguchi , Takahiro Kamio , Akihito Kojima , Masahiro Sugihara , Kensei Yamaguchi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Discussion Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer

Clinical Trial Registration Number

NCT03329690

Citation

J Clin Oncol 38: 2020 (suppl; abstr 4513)

DOI

10.1200/JCO.2020.38.15_suppl.4513

Abstract #

4513

Poster Bd #

121

Abstract Disclosures

Similar Posters

First Author: Kensei Yamaguchi

First Author: Takayuki Yoshino

First Author: Kohei Shitara

First Author: Ian E. Krop